|
1
|
Schwab CL, English DP, Roque DM, Pasternak
M and Santin AD: Past, present and future targets for immunotherapy
in ovarian cancer. Immunotherapy. 6:1279–1293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Seidman JD, Vang R, Ronnett BM,
Yemelyanova A and Cosin JA: Distribution and case-fatality ratios
by cell-type for ovarian carcinomas: A 22-year series of 562
patients with uniform current histological classification. Gynecol
Oncol. 136:336–340. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thériault BL, Cybulska P, Shaw PA, Gallie
BL and Bernardini MQ: The role of KIF14 in patient-derived primary
cultures of high-grade serous ovarian cancer cells. J Ovarian Res.
7:1232014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ottolina J, Ferrandina G, Gadducci A,
Scollo P, Lorusso D, Giorda G, Breda E, Savarese A, Candiani M,
Zullo F and Mangili G: Is the endometrial evaluation routinely
required in patients with adult granulosa cell tumors of the ovary?
Gynecol Oncol. 136:230–234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pham E, Birrer MJ, Eliasof S, Garmey E,
Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, et al:
Translational impact of nanoparticle-drug conjugate CRLX101 with or
without bevacizumab in advanced ovarian cancer. Clin Cancer Res.
21:808–818. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang X, Shen F, Hu W, Coleman RL and Sood
AK: New ways to successfully target tumor vasculature in ovarian
cancer. Curr Opin Obstet Gynecol. 27:58–65. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bian Z, Yu Y, Quan C, Guan R, Jin Y, Wu J,
Xu L, Chen F, Bai J, Sun W and Fu S: RPL13A as a reference gene for
normalizing mRNA transcription of ovarian cancer cells with
paclitaxel and 10-hydroxycamptothecin treatments. Mol Med Rep.
11:3188–3194. 2015.PubMed/NCBI
|
|
8
|
Ye H, Karim AA and Loh XJ: Current
treatment options and drug delivery systems as potential
therapeutic agents for ovarian cancer: A review. Mater Sci Eng C
Mater Biol Appl. 45:609–619. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun X, Lou LG, Sui DH and Wu XH:
Preclinical activity of lobaplatin as a single agent and in
combination with taxanes for ovarian carcinoma cells. Asian Pac J
Cancer Prev. 15:9939–9943. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shen H, Cai M, Zhao S, Wang H, Li M, Yao S
and Jiang N: CYR61 overexpression associated with the development
and poor prognosis of ovarian carcinoma. Med Oncol. 31:1172014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vermeersch KA, Wang L, McDonald JF and
Styczynski MP: Distinct metabolic responses of an ovarian cancer
stem cell line. BMC Syst Biol. 8:1342014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen K, Ma H, Li L, Zang R, Wang C, Song
F, Shi T, Yu D, Yang M, Xue W, et al: Genome-wide association study
identifies new susceptibility loci for epithelial ovarian cancer in
Han Chinese women. Nat Commun. 5:46822014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zeller C, Hinzmann B, Seitz S, Prokoph H,
Burkhard-Goettges E, Fischer J, Jandrig B, Schwarz LE, Rosenthal A
and Scherneck S: SASH1: A candidate tumor suppressor gene on
chromosome 6q24.3 is downregulated in breast cancer. Oncogene.
22:2972–2983. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rimkus C, Martini M, Friederichs J,
Rosenberg R, Doll D, Siewert JR, Holzmann B and Janssen KP:
Prognostic significance of downregulated expression of the
candidate tumour suppressor gene SASH1 in colon cancer. Br J
Cancer. 95:1419–1423. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gambetta MC and Muller J: O-GlcNAcylation
prevents aggregation of the polycomb group repressor polyhomeotic.
Dev Cell. 31:629–639. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McCorvie TJ, Kopec J, Hyung SJ,
Fitzpatrick F, Feng X, Termine D, Strain-Damerell C, Vollmar M,
Fleming J, Janz JM, et al: Inter-domain communication of human
cystathionine beta synthase: Structural basis of
S-adenosyl-L-methionine activation. J Biol Chem. 289:36018–36030.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Courcet JB, Elalaoui SC, Duplomb L, Tajir
M, Riviere JB, Thevenon J, Gigot N, Marle N, Aral B, Duffourd Y, et
al: Autosomal-recessive SASH1 variants associated with a new
genodermatosis with pigmentation defects, palmoplantar keratoderma
and skin carcinoma. Eur J Hum Genet. 23:957–962. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dauphinee SM, Clayton A, Hussainkhel A,
Yang C, Park YJ, Fuller ME, Blonder J, Veenstra TD and Karsan A:
SASH1 is a scaffold molecule in endothelial TLR4 signaling. J
Immunol. 191:892–901. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tolcher AW, Khan K, Ong M, Banerji U,
Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D,
Garrett CR, et al: Anti-tumour activity in RAS-driven tumours by
blocking AKT and MEK. Clin Cancer Res. 21:739–748. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takata A, Terauchi M, Hiramitsu S, Uno M,
Wakana K and Kubota T: Dkk-3 induces apoptosis through
mitochondrial and Fas death receptor pathways in human mucinous
ovarian cancer cells. Int J Gynecol Cancer. 25:372–379. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao X, Zhou Y, Nie M, Xian S, Chen H, Wen
Y, Zhang L, Huang Y, Chen M and Wang S: EMSY promoted the growth
and migration of ovarian cancer cells. Tumour Biol. 36:3085–3092.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Meng Q, Zheng M, Liu H, Song C, Zhang W,
Yan J, Qin L and Liu X: SASH1 regulates proliferation, apoptosis
and invasion of osteosarcoma cell. Mol Cell Biochem. 373:201–210.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin S, Zhang J, Xu J, Wang H, Sang Q, Xing
Q and He L: Effects of SASH1 on melanoma cell proliferation and
apoptosis in vitro. Mol Med Rep. 6:1243–1248. 2012.PubMed/NCBI
|
|
24
|
Yang L, Liu M, Gu Z, Chen J, Yan Y and Li
J: Overexpression of SASH1 related to the decreased invasion
ability of human glioma U251 cells. Tumour Biol. 33:2255–2263.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zeppernick F and Meinhold-Heerlein I: The
new FIGO staging system for ovarian, fallopian tube and primary
peritoneal cancer. Arch Gynecol Obstet. 290:839–842. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang S, Zhao X, Wang J, Wen Y, Zhang L,
Wang D, Chen H, Chen Q and Xiang W: Upregulation of microRNA-203 is
associated with advanced tumor progression and poor prognosis in
epithelial ovarian cancer. Med Oncol. 30:6812013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sasano T, Mabuchi S, Kuroda H, Kawano M,
Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe
A, et al: Preclinical efficacy for AKT targeting in clear cell
carcinoma of the ovary. Mol Cancer Res. 13:795–806. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Colombo PE, Boustta M, Poujol S, Jarlier
M, Bressolle F, Teulon I, Ladjemi MZ, Pinguet F, Rouanet P and Vert
M: Intraperitoneal administration of novel doxorubicin loaded
polymeric delivery systems against peritoneal carcinomatosis:
Experimental study in a murine model of ovarian cancer. Gynecol
Oncol. 122:632–640. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pereira A, Pérez-Medina T, Magrina JF,
Magtibay PM, Rodríguez-Tapia A, Peregrin I, Mendizabal E and
Ortiz-Quintana L: International federation of gynecology and
obstetrics staging classification for cancer of the ovary,
fallopian tube and peritoneum: Estimation of survival in patients
with node-positive epithelial ovarian cancer. Int J Gynecol Cancer.
25:49–54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grigoriadis C, Eleftheriades M,
Panoskaltsis T, Bacanu AM, Vitoratos N, Kondi-Pafiti A, Tsangkas A,
Tympa A and Hassiakos D: Ovarian cancer diagnosed during pregnancy:
Clinicopathological characteristics and management. G Chir.
35:69–72. 2014.PubMed/NCBI
|
|
32
|
Baratta MG, Schinzel AC, Zwang Y,
Bandopadhayay P, Bowman-Colin C, Kutt J, Curtis J, Piao H, Wong LC,
Kung AL, et al: An in-tumor genetic screen reveals that the BET
bromodomain protein, BRD4, is a potential therapeutic target in
ovarian carcinoma. Proc Natl Acad Sci USA. 112:232–237. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song Y, Xin X, Zhai X, Xia Z and Shen K:
Sequential combination therapy with flavopiridol and autocatalytic
caspase-3 driven by amplified hTERT promoter synergistically
suppresses human ovarian carcinoma growth in vitro and in mice. J
Ovarian Res. 7:1212014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Taube ET, Denkert C, Pietzner K, Dietel M,
Sehouli J and Darb-Esfahani S: Prognostic impact of neuroendocrine
differentiation in high-grade serous ovarian carcinoma. Virchows
Arch. 466:333–342. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chao A, Lai CH, Chen HC, Lin CY, Tsai CL,
Tang YH, Huang HJ, Lin CT, Chen MY, Huang KG, et al: Serum
microRNAs in clear cell carcinoma of the ovary. Taiwan J Obstet
Gynecol. 53:536–541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhu L, Hu Z, Liu J, Gao J and Lin B: Gene
expression profile analysis identifies metastasis and
chemoresistance-associated genes in epithelial ovarian carcinoma
cells. Med Oncol. 32:4262015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jeong HJ, Kim HJ, Lee EH, Lee HW and Kim
MK: Perimenopausal ovarian carcinoma patient with subclavian node
metastasis proven by immunohistochemistry. J Menopausal Med.
20:43–46. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nafisi H, Cesari M, Karamchandani J,
Balasubramaniam G and Keith JL: Metastatic ovarian carcinoma to the
brain: An approach to identification and classification for
neuropathologists. Neuropathology. 35:122–129. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Resta G, Vedana L, Marino S, Scagliarini
L, Bandi M and Anania G: Isolated splenic metastasis of ovaric
cancer. Case report and literature review. G Chir. 35:181–184.
2014.PubMed/NCBI
|
|
40
|
Kumar PM and Manisha M: Epidural hematoma
secondary to solitary skull metastasis from an ovarian carcinoma.
Asian J Neurosurg. 9:112–114. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Longo R, Platini C, Eid N, Elias-Matta C,
Buda T, Nguyen D and Quétin P: A late, solitary brain metastasis of
epithelial ovarian carcinoma. BMC Cancer. 14:5432014. View Article : Google Scholar : PubMed/NCBI
|
